Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMB7CPG)

Drug Name

Elsiglutide Drug Info

Synonyms

Tide ZP-1846; ZP-1846; GLP-2 analog (chemotherapy-induced diarrhoea), Zealand Pharma

Indication

Disease Entry	ICD 11	Status	REF
Diarrhea	ME05.1	Phase 2	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucagon-like peptide 2 receptor (GLP2R)	TT1YWO5	GLP2R_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Glucagon-like peptide 2 receptor (GLP2R)	DTT	GLP2R	1.807	2.138	2.202	2.632

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Diarrhea

ICD Disease Classification

ME05.1

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Glucagon-like peptide 2 receptor (GLP2R)	DTT	GLP2R	6.12E-01	0.06	0.3

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT01543451) Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea. U.S. National Institutes of Health.
2	Poster Abstracts. Volume 10, Issue Supplement S8, pages 126-209, December 2014.